Sales and Marketing

Showing 15 posts of 11524 posts found.

Merck and Schering-Plough propose shareholder settlement

July 28, 2009 Sales and Marketing MA, Merck

Merck and Schering-Plough's legal battles with their shareholders may be approaching a truce. Two class action lawsuits earlier this year …

GSK to co-market Amgen’s osteoporosis drug in Europe

July 28, 2009 Sales and Marketing Amgen, Deals, GSK

GlaxoSmithKline has signed a major deal with Amgen to co-market its new osteoporosis treatment denosumab in Europe, Australia, New Zealand …

Sales strategies for a changing environment

July 24, 2009 Sales and Marketing market access, sales, strategy

Over the last two years the UK pharma industry's established product sales strategies have begun to change. The industry's primary …

BMS buys Medarex for $2.1 billion

July 24, 2009 Research and Development, Sales and Marketing BMS, MA, Medarex

Bristol-Myers Squibb is to spend $2.1 billion in buying Medarex, the human antibody drug discovery specialists. Princeton-based Medarex is best …

Generic losses outweigh pandemic pluses for GSK

July 23, 2009 Sales and Marketing GSK

GlaxoSmithKline has reported a 2% fall in sales for the second quarter as growing generic competition in the US bites. …

Lupus drug shows surprise phase III success

July 23, 2009 Research and Development, Sales and Marketing Benlysta, GSK, HGS, Lupus

 GSK and Human Genome Sciences’ lupus drug Benlysta has surprised analysts by showing unexpectedly positive results in a pivotal late-stage …

Kennedy calls for overhaul of NICE processes

July 23, 2009 Research and Development, Sales and Marketing NICE, hta

NICE has come under fire over its lack of transparency and its relationship with the industry, following an inquiry by …

Advertising: be brief, be bold

July 22, 2009 Sales and Marketing Pfizer, advertising, branding

In the pharma industry, do we believe that the gap between what our businesses promise and what results our businesses …

NICE approves MabThera for leukaemia

July 22, 2009 Research and Development, Sales and Marketing MabThera, NICE

NICE has approved Roche's top-selling drug MabThera as a first-line treatment for the UK's most common type of leukaemia. The …

Tracleer expansion fuels Actelion growth

July 22, 2009 Sales and Marketing Actelion, Tracleer

Sales of pulmonary arterial hypertension treatment Tracleer are continuing to grow worldwide, helping to boost the fortunes of Actelion. The …

Roche eyes expanded colon cancer label for Xeloda

July 20, 2009 Research and Development, Sales and Marketing Roche, Xeloda

Roche is set to expand Xeloda's colon cancer indication, after a new combination of the drug was shown to increase …
The Gateway to Local Adoption Series

Latest content